Cryobiopsy Versus Forceps Biopsy for Pulmonary Lesions

Study summary

Purpose: Patients with peripheral lung nodules require evaluation for lung cancer. Our aim is to assess the diagnostic yield of a new technique, transbronchial cryobiopsies, in patients at risk for lung cancer. Target population: Patients referred for bronchoscopy and lung biopsies as a part of their work up for peripheral lung lesions. Procedures: Patients enrolled will have forceps transbronchial biopsies followed by transbronchial cryobiopsies for their lung lesion during bronchoscopy.

Ask AI to explain this study

Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedtransbronchial biopsy

The study team can explain what participation involves.

Who it may be forSolitary Pulmonary Nodule · Multiple Pulmonary Nodules

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 25, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?University of Pennsylvania

Study sponsor

Study overview

What this study is about

Purpose: Diagnostic
Study type: Interventional
Phase: Not applicable
Sponsor: University of Pennsylvania
Interventions being studied: Procedure: transbronchial biopsy

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. Age \>/= 18 2. At least one peripheral lung lesion \>8mm documented on CT scan referred for diagnostic bronchoscopy 3. Subject is able to undergo informed consent

Reasons someone may not be able to joinExclusion criteria

1. Coagulopathy (platelet count \< 50,000, INR \> 1.5) detected on blood testing done within 6 weeks of the procedural visit 2. Lesion associated with a prominent vessel evident on CT scan 3. Pure ground glass lesion 4. Fibrotic interstitial lung abnormalities on chest CT 5. Bullous emphysema in region of nodule 6. Supplemental oxygen utilization at baseline 7. BMI \> 40 8. End stage renal disease

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of PennsylvaniaPhiladelphia, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 25, 2020. Always confirm current availability with the study team.

View original record ↗